GlassScriptPhysician profile
Joseph Daniel Mock
NPI 1194111005
$6,931.90
in general payments reported to CMS, 2019-2025
66 companies · $1,879 in 2025
The $1,879 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $1,594 · 2023: $1,771 · 2024: $1,442 · 2025: $1,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,652 · Long Term Medical Supply Or Device Loan: $283 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,652.26 |
| Long Term Medical Supply Or Device Loan | $282.73 |
| Education | $157.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,256.45 | 2022-2025 | |
| Astellas Pharma US INC | $468.71 | 2022-2025 | Vyloy, Padcev, Xtandi |
| Pfizer INC. | $343.66 | 2022-2025 | |
| Genentech USA, INC. | $307.52 | 2021-2025 | Itovebi, Lunsumio, Polivy |
| Incyte Corporation | $250.29 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $244.65 | 2021-2025 | Opdualag, Opdivo, Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $201.44 | 2021-2025 | |
| Eisai INC. | $194.83 | 2022-2025 | |
| Glaxosmithkline, LLC. | $194.12 | 2023-2025 | Zejula, Ojjaara |
| Daiichi Sankyo INC. | $190.72 | 2021-2024 | Enhertu |
| Abbvie INC. | $181.84 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $180.67 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $172.78 | 2022-2025 | Darzalex, Tecvayli, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $140.35 | 2023-2025 | Tagrisso, Lynparza, Imfinzi |
| Alnylam Pharmaceuticals INC. | $134.22 | 2021-2025 | Givlaari |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $113.13 | 2021-2025 | Brukinsa |
| Celgene Corporation | $112.51 | 2022-2024 | Pomalyst, Reblozyl, Opdualag |
| Ipsen Biopharmaceuticals, INC | $98.70 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
| Servier Pharmaceuticals LLC | $97.81 | 2021-2025 | |
| Genzyme Corporation | $94.44 | 2022-2023 | |
| Legend Biotech USA INC. | $93.82 | 2025 | Carvykti |
| Seagen INC. | $88.76 | 2021-2023 | Tukysa, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $88.73 | 2021-2025 | Ninlaro, Iclusig |
| Puma Biotechnology, INC. | $87.11 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $83.31 | 2023-2024 | Libtayo |
| Array Biopharma INC | $72.44 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Adc Therapeutics America, INC. | $72.09 | 2022-2025 | |
| Genmab U.S., INC. | $71.21 | 2024 | Epkinly |
| Lilly USA, LLC | $70.61 | 2022-2023 | Verzenio, Retevmo, Jaypirca |
| Gilead Sciences, INC. | $69.84 | 2023-2025 | Trodelvy |
| Taiho Oncology, INC. | $65.62 | 2022-2023 | |
| Amgen INC. | $65.10 | 2022-2023 | Lumakras, Nplate, Xgeva |
| Mirati Therapeutics, INC. | $64.40 | 2023 | Krazati |
| Novocure INC. | $63.87 | 2024-2025 | Optune, Optune Lua (Novottf-200t), Optune Gio |
| Tactile Systems Technology INC | $56.17 | 2022 | |
| Tersera Therapeutics LLC | $52.14 | 2022-2025 | Quzyttir |
| Tempus Ai, INC | $52.00 | 2024-2025 | Xt Cdx |
| Karyopharm Therapeutics INC. | $46.26 | 2023-2025 | Xpovio |
| Pharmaessentia USA Corporation | $44.42 | 2022-2023 | Besremi |
| Sumitomo Pharma America, INC. | $42.77 | 2023-2025 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $42.38 | 2022-2023 | Imbruvica |
| Cti Biopharma Corp. | $40.44 | 2023 | Vonjo |
| Sobi, INC | $40.30 | 2022-2025 | |
| Myovant Sciences INC. | $32.88 | 2021-2022 | |
| Stemline Therapeutics INC. | $31.08 | 2023 | Orserdu |
| Geron Corporation | $30.62 | 2025 | Rytelo |
| Emd Serono, INC. | $30.14 | 2024 | |
| Exelixis INC. | $28.86 | 2022 | |
| Deciphera Pharmaceuticals INC. | $26.45 | 2025 | Qinlock |
| Syndax Pharmaceuticals, INC. | $24.12 | 2025 | |
| Caris Mpi, INC. | $20.05 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $19.90 | 2025 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $19.73 | 2024 | Ultomiris |
| G1 Therapeutics, INC. | $19.21 | 2023 | Cosela |
| Immunocore Limited | $18.79 | 2025 | Kimmtrak |
| Rigel Pharmaceuticals, INC. | $18.42 | 2023 | Rezlidhia, Tavalisse |
| Acrotech Biopharma INC. | $17.83 | 2024 | Beleodaq |
| Spectrum Pharmaceuticals INC. | $17.24 | 2024 | Rolvedon |
| Progenics Pharmaceuticals, INC. | $17.05 | 2024 | |
| Beone Medicines USA, INC. | $16.90 | 2025 | Brukinsa |
| Coherus Oncology, INC. | $16.58 | 2024 | |
| Pharmacosmos Therapeutics INC. | $15.73 | 2025 | Monoferric |
| Aveo Pharmaceuticals, INC. | $15.14 | 2022 | |
| Adaptive Biotechnologies Corporation | $14.57 | 2025 | Clonoseq |
| Cumberland Pharmaceuticals, INC. | $14.45 | 2025 | Sancuso |
| Azurity Pharmaceuticals, INC. | $13.53 | 2025 | Danziten |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.